Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8355)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 26, 2018 (publication date) through Jul 12, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v6/i12/514.htm |
| Number | Citing Articles |
| 1 |
Kuo-Hsuan Huang, Wei-Chen Tai, Feng-Woey Tsay, Pin-I Hsu, Deng-Chyang Wu, Song-Seng Loke, Chih-Chien Yao, Seng-Kee Chuah, Chih-Ming Liang. Efficacy and safety of ten-day bismuth quadruple therapy for first-line anti-Helicobacter pylori infection in the elderly- A multicenter real-world report. Journal of Microbiology, Immunology and Infection 2025; doi: 10.1016/j.jmii.2025.06.010
|
| 2 |
Liem T. Nguyen, Vuong B. Nguyen, Tu V. Tran, Loan T. T. Le, Mai H. T. Phuong, Thang Nguyen. Effects of the EM CYP2C19 type and MDR1 3435CC gene on Helicobacter pylori eradication rate in patients with duodenal ulcer by the four-drug regimen of rabeprazole, bismuth, tetracycline, and tinidazole. Pharmacia 2024; 71: 1 doi: 10.3897/pharmacia.71.e108090
|
| 3 |
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first‐line triple therapy. Helicobacter 2019; 24(3) doi: 10.1111/hel.12574
|
| 4 |
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng.
The Effect of
CYP2C19
Gene Polymorphism on the Eradication Rate of
Helicobacter Pylori
by Proton Pump Inhibitors-ContAining Regimens in Asian Populations: a Meta-Analysis
. Pharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
|
| 5 |
Danli Zhou, Wuyu Wang, Lan Gu, Meiling Han, Wujuan Hao, Junfeng Huang, Qiong Lin, Yan Wang. Helicobacter pylori antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategies. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1392787
|
| 6 |
He-Jian Zhang, Xue-Hui Zhang, Jie Liu, Lu-Ning Sun, Yi-Wen Shen, Chen Zhou, Hong-Wen Zhang, Li-Jun Xie, Juan Chen, Yun Liu, Yong-Qing Wang. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacological Research 2020; 152: 104606 doi: 10.1016/j.phrs.2019.104606
|
| 7 |
Wen Gao, Hui Ye, Xin Deng, Chi Wang, Ying Xu, Yixuan Li, Xuezhi Zhang, Hong Cheng. Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study. Helicobacter 2020; 25(5) doi: 10.1111/hel.12717
|